Immunome’s Varegacestat shows dramatic results in Phase 3 desmoid tumor trial
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
The update promises to revolutionize laboratory workflows by optimizing resources
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
The move strengthens GBL’s clinical-stage presence in the United States
The combination also outperformed chemotherapy on another important secondary endpoint
The receipt of this permission paves way for the marketing of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) in India
Patients with BRCA mutations often face aggressive disease and poor prognosis
Subscribe To Our Newsletter & Stay Updated